Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Shruti Agrawal"'
Publikováno v:
SSRN Electronic Journal.
Higher education institutions play a very important role in the sustainable economic and social development of a country. They provide a platform to its students for developing and enhancing their academic, social, and employability skills. In develo
Autor:
Rachel Bousfield, Esther Daubney, Martin D. Curran, M. Estée Török, Deborah White, Theodore Gouliouris, Iain Kean, Stephen Baker, John A. Clark, Shruti Agrawal, David Inwald, Nazima Pathan, Adam Palmer, Elizabeth Powell
Publikováno v:
Wellcome Open Research. 6:119
Background: Broad-spectrum antimicrobial therapy is a key driver of antimicrobial resistance. Here, we aimed to review indications for antimicrobial therapy, determine the proportion of suspected bacterial infections that are confirmed by culture, an
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:58-66
Nivolumab is a fully human monoclonal antibody that inhibits programmed death-1 activation. The clinical pharmacology profile of nivolumab was analyzed by a population pharmacokinetics model that assessed covariate effects on nivolumab concentrations
Autor:
Mathangi Gopalakrishnan, J. Shen, Jogarao V. S. Gobburu, Amit Roy, Shruti Agrawal, Paul Statkevich, Yan Feng, Brian J. Schmidt, Akintunde Bello, Vijay Ivaturi, Xiaochen Zhao, V. Goodman
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 31(2)
Background Nivolumab 480 mg every 4 weeks (Q4W) is approved in the European Union, United States, and several other markets across multiple tumor types. Its approval was supported by quantitative efficacy/safety analyses bridging to 3 mg/kg every 2 w
Autor:
Amit Roy, M. Rashford, Georgina V. Long, Claus Garbe, Linda Rollin, J.G. Schneider, Gwenaelle Gravis, Akintunde Bello, Elena Grigoryeva, Xiaochen Zhao, Shruti Agrawal, Scott S. Tykodi
Publikováno v:
Annals of Oncology
Annals of Oncology, 2018, 29 (11), pp.2208-2213. ⟨10.1093/annonc/mdy408⟩
Annals of Oncology, Elsevier, 2018, 29 (11), pp.2208-2213. ⟨10.1093/annonc/mdy408⟩
Annals of Oncology, 2018, 29 (11), pp.2208-2213. ⟨10.1093/annonc/mdy408⟩
Annals of Oncology, Elsevier, 2018, 29 (11), pp.2208-2213. ⟨10.1093/annonc/mdy408⟩
Background A nivolumab monotherapy flat-dosing regimen of 480 mg every 4 weeks (Q4W) has been approved in several markets, including the United States, Canada, and European Union, as an alternative dosing regimen for several indications. Approvals of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16548b37e4051104ab356a5c7edca355
https://hal-amu.archives-ouvertes.fr/hal-02143540
https://hal-amu.archives-ouvertes.fr/hal-02143540
Autor:
Akintunde Bello, Xiaoning Wang, J. Shen, A. Achanta, H.E. Vezina, Yan Feng, Xiaochen Zhao, M. Hruska, Shruti Agrawal, Satyendra Suryawanshi, M.B. McHenry, Amit Roy, Ian M. Waxman
Publikováno v:
Annals of Oncology
Background Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, flat dosing is expected to shorten preparation time and improve e
Autor:
Jong-Soon Park, Yan Feng, Brian Lestini, Gaurav Bajaj, Friedrich Graf Finckenstein, Amit Roy, Xiaoning Wang, Shruti Agrawal, Akintunde Bello
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(18)
Purpose: Nivolumab is a fully human IgG4 monoclonal antiprogrammed death-1 antibody with demonstrated efficacy, including durable responses and prolonged survival, in patients with previously treated, advanced non–small cell lung cancer (NSCLC). Ex
Autor:
Iain R. Macpherson, Patricia Lo Russo, T.R. Jeffry Evans, George D. Demetri, Prashni Paliwal, Shruti Agrawal, Valerie G. Brunton, Jeffrey A. Morgan, Maurizio Voi, Ding Wang
Publikováno v:
Clinical Cancer Research. 15:6232-6240
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists. Experimental Des
Publikováno v:
International Journal of Medical Science and Public Health. 5:2435
Background: In today’s modern health-care practice, transfusion medicine is an important component of it. Safe blood supply and transfusion is one of the major issues in transfusion medicine. Potential blood donors may not be able to donate blood f
Publikováno v:
Blood. 116:4938-4938
Abstract 4938 Introduction: Dasatinib 100 mg once daily (QD) has superior efficacy compared with imatinib in patients with newly diagnosed CML-CP, as demonstrated by a randomized phase 3 trial in this setting (CA180-056/DASISION; Kantarjian et al, N